Winton Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Winton Group’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,663	Closed	-$244K	–	955
2021 Q4	$244K	Buy	+10,663	New	+$253K	0.01%	894

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Winton Group's AUPH Position: Q1 2022 in Review

Winton Group sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 10,663 shares — an estimated $244K sold.

Winton Group first reported a position in AUPH in Q4 2021 and held it in 1 quarter. The position peaked at $244K in Q4 2021. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

Winton Group reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Winton Group sold 10,663 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $244K.
Winton Group first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Winton Group's Aurinia Pharmaceuticals position peaked at $244K in Q4 2021.
184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on Winton Group's 13F filing for Q1 2022, filed 11 May 2022.